Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 and CFZ533 in Systemic Lupus Erythematosus (SLE)
NCT03656562Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of ianalumab and iscalimab in systemic lupus erythematosus (SLE) (4 cohorts), sponsored by Novartis. Primary endpoint: SLE Responder Index-4 Response Status at 29 weeks. Started Dec 2018; status: completed.
02
Drugs
ianalumabiscalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03656562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656562.